| Literature DB >> 27938369 |
Freya J I Fowkes1,2,3,4, Bridget L Draper5, Margaret Hellard5,6, Mark Stoové5,6.
Abstract
BACKGROUND: The global health community is currently transitioning from the Millennium Development Goals (MDGs) to the Sustainable Development Goals (SDGs). Unfortunately, progress towards maternal, newborn and infant health MDGs has lagged significantly behind other key health goals, demanding a renewed global effort in this key health area. The World Health Organization and other institutions heralded integrated antenatal care (ANC) as the best way to address the inter-related health issues of HIV, tuberculosis (TB) and malaria in the high risk groups of pregnant women and infants; integrated ANC services also offer a mechanism to address slow progress towards improved maternal health. DISCUSSION: There is remarkably limited evidence on best practice approaches of program implementation, acceptability and effectiveness for integrated ANC models targeting multiple diseases. Here, we discuss current integrated ANC global guidelines and the limited literature describing integrated ANC implementation and evidence for their role in addressing HIV, malaria and TB during pregnancy in sub-Saharan Africa. We highlight the paucity of data on the effectiveness of integrated ANC models and identify significant structural barriers in the health system (funding, infrastructure, distribution, human resources), the adoption system (limited buy-in from implementers, leadership, governance) and, in the broader context, patient-centred barriers (fear, stigma, personal burdens) and barriers in funding structures. We highlight recommendations for action and discuss avenues for the global health community to develop systems to integrate multiple disease programs into ANC models of care that better address these three priority infectious diseases. With the current transition to the SDGs and concerns regarding the failure to meet maternal health MDGs, the global health community, researchers, implementers and funding bodies must work together to ensure the establishment of quality operational and implementation research to inform integrated ANC models. It is imperative that the global health community engages in a timely discussion about such implementation innovations and instigates appropriate actions to ensure advances in maternal health are sufficient to meet applicable SDGs.Entities:
Keywords: Antenatal care; HIV; Integrated services; Malaria; Tuberculosis
Mesh:
Year: 2016 PMID: 27938369 PMCID: PMC5151135 DOI: 10.1186/s12916-016-0753-9
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Millennium and Sustainable Development Goals addressing HIV, TB and malaria or maternal, newborn and child health and sub-Saharan African achievements and statistics
| Millennium Development Goals [ | 2015 sub-Saharan Africa achievement [ |
| Goal 4: Reduce Child Mortality | |
| Target 5: Reduce by two-thirds, between 1990 and 2015, the under-five mortality rate | 52% reduction in child mortality |
| Goal 5: Improve Maternal Health | |
| Target 6: Reduce by three-quarters, between 1990 and 2015, the maternal mortality ratio | 49% reduction in maternal mortality ratio |
| Goal 6: Combat HIV/AIDS, Malaria and Other Diseases | |
| Target 7: Have halted by 2015 and begun to reverse the spread of HIV/AIDS | 51% reduction in new HIV infections |
| Target 8: Have halted by 2015 and begun to reverse the incidence of malaria and other major diseases | 69% reduction in malaria mortality in the under-five age group |
| Sustainable Development Goals [ | 2015 sub-Saharan burden of disease |
| Goal 3: Good Health and Well-being | |
| 3.1: By 2030, reduce the global maternal mortality ratio to less than 70 per 100,000 live births | 546 per 100,000 live births [ |
| 3.2: By 2030, end preventable deaths of newborns and under-five children, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1000 live births and under-five mortality to at least as low as 25 per 1000 live births | Neonatal and under-five mortality is 29 and 83 per 1000 live births, respectively [ |
| 3.3: By 2030, end the epidemics of AIDS, TB, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases | 2.6 (0–20.1) new HIV infections per 1000 uninfected populationa [ |
| 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential healthcare services and access to safe, effective, quality and affordable essential medicines and vaccines for all | HIV treatment coverage 0–70%b [ |
ITN insecticide-treated net, TB tuberculosis, IPTp intermittent preventive therapy in pregnancy
a2014 statistics for WHO Africa region
b2015 statistics for WHO Africa region
WHO guidelines, national guidelines and implementation coverage on HIV, malaria, TB, prevention, screening and treatment during pregnancy in sub-Saharan Africa
| Intervention | WHO recommendationsa | Inclusion in national guidelinesb | Coverage (%)c; median (range) |
|---|---|---|---|
| HIV | |||
| Prevention | ART prophylaxis from 14 weeks for PMTCT | Yes | No data |
| Screening | HIV testing at first ANC visit | Yes | 37.9% |
| Treatment | ART for mother starting immediately if CD4 count ≤ 350 cells/mm3 for mother’s own health (treatment of HIV and PMTCT) | Sometimes | No data |
| Malaria | |||
| Prevention | IPTp at each ANC visit from 2nd trimester to delivery, doses ≥ 1 month apart, preferably DOT | Sometimes | 6.6% |
| Receive one LLIN through ANC visits | Sometimese | 39.7% | |
| Screening | No guidelines | N/A | N/A |
| Treatment | ‘Effective case management’ – presumptive treatment of symptoms/fever as per national guidelines | Rarely | No data |
| TB | |||
| Prevention | TB infection control in PMTCT settings | No | No data |
| Screening | TB signs and/or symptoms should be evaluated for active TB | Rarely | No data |
| Treatment | All first-line TB drugs (except streptomycin) | No | No data |
ANC antenatal care, ART antiretroviral therapy, DOT directly observed treatment, IPTp intermittent preventive therapy in pregnancy, ITN insecticide-treated net, LLIN long-lasting insecticide-treated net, SP sulfadoxine-pyrimethamine, TB tuberculosis, PMTCT prevention of mother-to-child transmission
aAdapted from WHO guidelines [78–85]
bNational Guidelines of the nine countries (Botswana, Tanzania, Uganda, Liberia, Mozambique, Namibia, Nigeria, South Africa, and Swaziland) with accessible guidelines/policies/strategies on Ministry of Health (or similar) websites. The recommended components of ANC vary widely between and within countries, often depending on the level of care (community, district, regional or national) at which ANC is provided. Other components generally included in ANC are blood tests for blood group, anaemia, HIV and syphilis, urine dipstick for protein and glucose, checking blood pressure, providing tetanus toxoid, iron and folic acid, assessment of substance use, and performing nutrition and hygiene counselling
cImplementation coverage data is based on STATcompiler: The DHS Program. Data is median (range) coverage data available for HIV screening (data from four countries) and malaria prevention (IPTp 34 countries; ITN/LLIN 25 countries)
dCoverage is reported as percentage of women receiving 3+ doses of SP/Fansidar, with at least one dose during ANC visit (DOT)
eIncluding any reference to provision of LLINs, ITNs or mosquito nets in general
fPercentage coverage of pregnant women who slept under a LLIN the night before the survey
Key health system, adoption system and broader context barriers to integration of HIV, TB and malaria services into antenatal care
| Health system characteristics | |
| Insufficient resources and financial infrastructure | • Weak disease-specific and antenatal care program links |
| • Weak health systems | |
| • Financing of health services may be required to change to fit integration of previously separate services | |
| Inadequate physical and technical infrastructure | • Services provided at different locations |
| • Services not provided on same day | |
| Ineffective procurement and distribution systems | • Patient drug procurement/administration at different locations |
| • Inadequate and irregular supplies of essential drugs and interventions | |
| Inadequate information systems | • Weak monitoring and evaluation systems |
| Insufficient human resources | • Staff shortages and overburdened staff |
| • Frequently reallocated workforce | |
| Adoption system | |
| Insufficient buy-in from healthcare implementers | Buy in can be affected by: |
| • Limited human resource capacity, time, training and financing for extra | |
| • Service delivery tasks | |
| • Lack of supervision | |
| • Poor motivation | |
| Inconsistent leadership and governance | • Inconsistent national policies |
| • Inconsistent guidelines and training documents | |
| • Poor adherence to guidelines | |
| Broader context | |
| Patient-centred barriers to service delivery | • Attending multiple clinics on separate occasions/locations |
| • Time away from work/parenting obligations | |
| • Costly and timely transport options | |
| • Lack of partner support | |
| Cultural and social barriers | • Fear and stigma, lack of trust in interventions |
| • Societal attitudes towards HIV, tuberculosis, malaria | |
| Funding structures | • Historical focus on donor funding to specific diseases |
| • Siloed and disease-specific funding models | |
| • Complexities of different levels of government funding | |